|
| Deletion | Gain | Ewing's sample type | Frequency (%) | Technology | Study | Clinical significance |
|
| 1p | | ESFT | 17/184 (9%) | Karyotyping and CGH | Hattinger et al. [47]; Ozaki et al. [48] | |
| 1p36 | | ESFT | 5/88 (6%) | Karyotyping (G-Band) | Roberts et al. [49] | |
| 1p36.32-p36.11 | | ESFT | 2/9 (22%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
| 1q | ESFT | 77/396 (19%) | Karyotyping and CGH | Armengol et al. [51]; Brisset et al. [52]; Hattinger et al. [47]; Ozaki et al. [48]; Roberts et al. [49]; Savola et al. [53]; Tarkkanen et al. [54] | (i) Adverse event free survival (ii) Adverse overall survival (iii) Age at diagnosis >15 years (iv) Metastatic (trend) |
| | Cell line | 5/8 (63%) | CGH | Shing et al. [55] |
| 1q21-q22 | ESFT | 5/28 (18%) | CGH | Tarkkanen et al. [54] | (i) Adverse overall survival (trend) (ii) Adverse 5-year distant disease-free survival (trend) |
|
| 2 | ESFT | 38/262 (15%) | Karyotyping and CGH | Brisset et al. [52]; Hattinger et al. [47]; Roberts et al. [49], Savola et al. [53] | (i) Localized disease |
| 2q | ESFT | 12/62 (19%) | CGH | Ozaki et al. [48] | (i) Adverse overall survival |
|
| 3p | | Cell line | 3/8 (38%) | CGH | Shing et al. [55] | |
|
| 4p | ESFT | 10/105 (10%) | CGH | Brisset et al. [52]; Ozaki et al. [48] | (i) Relapse |
|
| 5 | ESFT | 28/231 (12%) | Karyotyping and CGH | Brisset et al. [52]; Hattinger et al. [47]; Roberts et al. [49] | |
| 5p | ESFT | 5/25 (20%) | CGH | Ferreira et al. [56] | |
|
| 6p21.1~pter | ESFT | 3/28 (11%) | CGH | Tarkkanen et al. [54] | (i) Adverse overall survival (ii) Adverse 5-year distant disease-free survival |
|
| 7 | ESFT | 26/216 (12%) | Karyotyping and CGH | Hattinger et al. [47]; Roberts et al. [49]; Tarkkanen et al. [54] | |
| 7p21.1-p11.2 | ESFT | 2/9 (22%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
| 7q (partial) | | ESFT | 6/25 (25%) | CGH | Ferreira et al. [56] | |
| 7q | ESFT | 5/28 (18%) | CGH | Tarkkanen et al. [54] | |
|
| 8 | ESFT | 197/413 (48%) | Karyotyping, CGH and FISH | Armengol et al. [51]; Brisset et al. [52]; Ferreira et al. [56]; Hattinger et al. [47]; Maurici et al. [57]; Ozaki et al. [48]; Savola et al. [53]; Tarkkanen et al. [54]; Zielenska et al. [58] | (i) Local recurrences (trend) (ii) Relapse (trend) (iii) Adverse overall survival (trend) (iv) Adverse 5-year distant disease-free survival (trend) |
| | Cell line | 8/8 (100%) | CGH | Shing et al. [55] |
| 8p | ESFT | 30/62 (48%) | CGH | Ozaki et al. [48] | (i) Relapse |
| 8q | ESFT | 32/62 (52%) | CGH | Ozaki et al. [48] | |
| 8q11.21-q22.3 | ESFT | 6/9 (67%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
| 8q24.11-q24.21 | ESFT | 7/9 (78%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
|
| 9p | | ESFT | 7/31 (23%) | CGH | Savola et al. [53] | |
| 9p21 | | ESFT | 50/291 (17%) | Karyotyping, CGH, FISH, Southern Blot, SNP Microarray (Affy 100 K), and MLPA | Brownhill et al. [59]; Huang et al. [60]; Kovar et al. [61]; Neale et al. [50]; Roberts et al. [49]; Savola et al. [62]; Wei et al. [63] | (i) Adverse event free survival (trend) (ii) Adverse overall survival(iii) Axial(iv) progressive disease (trend) (v) Poor chemoresponse |
| 9p21 | | Cell line | 24/43 (56%) | CGH (Agilent 44 K and 244 K), Taqman qRT-PCR, FISH, Southern Blot and MLPA | Brownhill et al. [59]; Kovar et al. [61]; Savola et al. [62] | |
| 9p21.3 | | Xenotransplant | 4/12 (33%) | dPCR, FISH | López-Guerrero et al. [64] | |
|
| 10 | | ESFT | 12/87 (14%) | CGH | Ferreira et al. [56]; Ozaki et al. [48] | |
|
| 11p | ESFT | 2/62 (3%) | | Ozaki et al. [48] | (i) Relapse |
| 11q | ESFT | 2/62 (3%) | | Ozaki et al. [48] | (i) Relapse |
|
| 12 | ESFT | 104/434 (24%) | Karyotyping, CGH and FISH | Armengol et al. [51]; Brisset et al [52]; Ferreira et al. [56]; Hattinger et al. [47]; Maurici et al. [57]; Roberts et al. [49]; Savola et al. [53]; Tarkkanen et al. [54]; Zielenska et al. [58] | (i) Adverse event free survival (ii) Adverse overall survival(iii) Relapse (trend) |
| 12p | ESFT | 12/62 (19%) | CGH | Ozaki et al. [48] | (i) Adverse overall survival |
| 12q | ESFT Cell line | 11/62 (18%) 6/8 (75%) | CGH CGH | Ozaki et al. [48]Shing et al. [55] | (i) Adverse overall survival |
| 12q14.1-q15 | ESFT | 2/9 (22%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
|
| 14 | ESFT | 11/143 (8%) | Karyotyping and CGH | Brisset et al. [52]; Hattinger et al. [47] | |
| 14q11.2 | ESFT | 2/9 (22%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
|
| 15 | ESFT | 4/43 (9%) | CGH | Brisset et al. [52] | |
|
| 16p | ESFT | 2/28 (7%) | CGH | Tarkkanen et al. [54] | |
| 16q | | ESFT | 69/396 (17%) | Karyotyping and CGH | Brisset et al. [52]; Ferreira et al. [56]; Hattinger et al. [47]; Ozaki et al. [48]; Roberts et al. [49]; Savola et al. [53]; Tarkkanen et al. [54] | (i) Adverse overall survival(ii) Age at diagnosis >15 years(iii) Disseminated disease at diagnosis |
| 16q | | Cell line | 5/8 (63%) | CGH | Shing et al. [55] | |
| 16q22.3 | | ESFT | 5/9 (56%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
|
| 17 | | ESFT and Xenotransplant | 2/19 (11%) | dPCR, FISH | López-Guerrero et al. [64] | |
| 17p | | ESFT Cell line | 9/62 (15%) 4/8 (50%) | CGH CGH | Ozaki et al. [48] Shing et al. [55] | (i) Adverse overall survival |
| 17p13 | | ESFT | 8/88 (9%) | Karyotyping (G-Band) | Roberts et al. [49] | |
| 17q21.31-q25.3 | ESFT | 6/9 (67%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
|
| 18 | ESFT | 6/68 (9%) | CGH | Brisset et al. [52]; Ferreira et al. [56] | |
|
| 19 | | ESFT | 4/25 (16%) | CGH | Ferreira et al. [56] | |
| 19p | | ESFT | 7/62 (11%) | CGH | Ozaki et al. [48] | |
| 19q | | ESFT | 11/62 (18%) | CGH | Ozaki et al. [48] | |
|
| 20 | ESFT | 35/248 (14%) | Karyotyping and CGH | Brisset et al. [52]; Ferreira et al. [56]; Hattinger et al. [47]; Roberts et al. [49] | (i) Adverse event free survival (ii) Adverse overall survival |
| 20p | ESFT | 11/62 (18%) | CGH | Ozaki et al. [48] | (i) Adverse overall survival |
| 20q | ESFT | 11/62 (18%) | CGH | Ozaki et al. [48] | (i) Adverse overall survival |
| 20q11.23-q13.33 | ESFT | 2/9 (22%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
|
| 21q22.3 | ESFT | 2/9 (22%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
| 22q11.21 | ESFT | 2/9 (22%) | SNP Microarray (Affy 100 K) | Neale et al. [50] | |
|
| Y | | Cell lines | 3/5 (60%) | CGH | Shing et al. [55] | |
|
